ORBIMED ADVISORS LLC
•CIK: 1055951•Filing: Q4 2025
ORBIMED ADVISORS LLC, managed by the seasoned team of Dr. Oscar Ortega and Dr. Carlos M. de la Cruz, is known for its concentrated, high-conviction investment strategy, focusing on biotech and healthcare sectors. Recently, the fund has made notable moves by adding Biogen Inc. (BSX) and CRISPR Therapeutics (CRNX) with significant weight increases, reflecting its aggressive growth-oriented approach amidst a dynamic biotech landscape.
Total AUM
$4.7B
+ $12.8M in options
QoQ Performance
+21.9%
Positions
101
+ 2 options
Top 10 Concentration
41.0%
Latest Filing
Q4 2025
Top Holdings Allocation
EWTX
LLY
EWTX8.1%
LLY6.8%
BSX4.9%
SVA3.9%
UPB3.3%
ISRG3.1%
SION3.1%
MBX2.6%
📈 Biggest Buys
📉 Biggest Sells
Sector Breakdown
Other88.2%
Healthcare11.8%
🚪 Exited Positionssold since Q3 2025
—
SCPHARMACEUTICALS INC
SOLD
$34.4M
+16 more exited positions
Changes from Q3 2025
NEW22 new positions
↑23 increased
↓35 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023